1887

Abstract

Human papillomavirus (HPV) virus-like particles (VLP) are emerging as the immunogen of choice for prophylactic vaccines. The inability to infect animals with HPV has prevented the testing of potential vaccines such as these in animal systems. This study describes the development of a recombinant vaccinia virus (VV)–HPV type 16 (HPV-16) VLP challenge model to evaluate the efficacy of the cell-mediated immune response following HPV-16 VLP immunization in mice. Inoculation of BALB/c and C57 BL/6 mice with HPV-16 VLP resulted in HPV VLP-specific T cell proliferative responses characterized by the production of both Th and Th cytokines, and afforded protection against virus challenge from recombinant VV expressing HPV-16 L1 (VVL1-16). Protection was demonstrated by a 4·6 log reduction in ovarian titres of VVL1-16 in vaccinated BALB/c mice and a 2·3 log reduction in vaccinated C57 BL/6 mice, compared with unvaccinated mice.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-80-9-2471
1999-09-01
2024-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jgv/80/9/0802471a.html?itemId=/content/journal/jgv/10.1099/0022-1317-80-9-2471&mimeType=html&fmt=ahah

References

  1. Alloub M. I., Barr B. B., McLaren K. M., Smith I. W., Bunney M. H., Smart G. E. 1989; Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. British Medical Journal 298:153–156
    [Google Scholar]
  2. Bachmann M. F., Kundig T. M., Freer G., Li Y., Kang C. Y., Bishop D. H., Hengartner H., Zinkernagel R. M. 1994; Induction of protective cytotoxic T cells with viral proteins. European Journal of Immunology 24:2228–2236
    [Google Scholar]
  3. Belyakov I. M., Derby M. A., Ahlers J. D., Kelsall B. L., Earl P., Moss B., Strober W., Berzofsky J. A. 1998; Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV–vaccinia challenge. Proceedings of the National Academy of Sciences USA 95:1709–1714
    [Google Scholar]
  4. Binder D., Kundig T. M. 1991; Antiviral protection by CD8+ versus CD4+ T cells. CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL. Journal of Immunology 146:4301–4307
    [Google Scholar]
  5. Bonnez W., DaRin C., Borkhuis C., de Mesy Jensen K., Reichman R. C., Rose R. C. 1998; Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. Journal of Virology 72:5256–5261
    [Google Scholar]
  6. Bosch F. X., Manos M. M., Muñoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. 1995; Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. Journal of the National Cancer Institute 87:796–802
    [Google Scholar]
  7. Boyum A. 1968; Separation of leukocytes from blood and bone marrow. Introduction. Scandinavian Journal of Clinical and Laboratory Investigation Supplement 97:7
    [Google Scholar]
  8. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J. T., Lowy D. R. 1995; Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology 69:3959–3963
    [Google Scholar]
  9. Chakrabarti S., Brechling K., Moss B. 1985; Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques . Molecular and Cellular Biology 5:3403–3409
    [Google Scholar]
  10. Christensen N. D., Reed C. A., Cladel N. M., Han R., Kreider J. W. 1996; Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. Journal of Virology 70:960–965
    [Google Scholar]
  11. Coleman N., Birley H. D., Renton A. M., Hanna N. F., Ryait B. K., Byrne M., Taylor-Robinson D., Stanley M. A. 1994; Immunological events in regressing genital warts. American Journal of Clinical Pathology 102:768–774
    [Google Scholar]
  12. De Bruijn M. L. H., Greenstone H. L., Vermeulen H., Melief C. J. M., Lowy D. R., Schiller J. T., Kast W. M. 1998; L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371–376
    [Google Scholar]
  13. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. 1997; Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microbial Pathogenesis 22:219–225
    [Google Scholar]
  14. Frazer I. H., Medley G., Crapper R. M., Brown T. C., Mackay I. R. 1986; Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men. Lancet ii:657–660
    [Google Scholar]
  15. Hagensee M. E., Yaegashi N., Galloway D. A. 1993; Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. Journal of Virology 67:315–322
    [Google Scholar]
  16. Jansen K. U., Rosolowsky M., Schultz L. D., Markus H. Z., Cook J. C., Donnelly J. J., Martinez D., Ellis R. W., Shaw A. R. 1995; Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13:1509–1514
    [Google Scholar]
  17. Kent S. J., Zhao A., Best S. J., Chandler J. D., Boyle D. B., Ramshaw I. A. 1998; Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. Journal of Virology 72:10180–10188
    [Google Scholar]
  18. Kirnbauer R. 1996; Papillomavirus-like particles for serology and vaccine development. Intervirology 39:54–61
    [Google Scholar]
  19. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. 1992; Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences USA 89:12180–12184
    [Google Scholar]
  20. Kirnbauer R., Chandrachud L. M., O’Neil B. W., Wagner E. R., Grindlay G. J., Armstrong A., McGarvie G. M., Schiller J. T., Lowy D. R., Campo M. S. 1996; Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37–44
    [Google Scholar]
  21. Lowy D. R., Kirnbauer R., Schiller J. T. 1994; Genital human papillomavirus infection. Proceedings of the National Academy of Sciences USA 91:2436–2440
    [Google Scholar]
  22. NIH 1996; Cervical cancer. Consensus Statement no 14 pp 1–38
    [Google Scholar]
  23. O’Neill H. C., Brenan M. 1987; A role for early cytotoxic T cells in resistance to ectromelia virus infection in mice. Journal of General Virology 68:2669–2673
    [Google Scholar]
  24. Peng S., Frazer I. H., Fernando G. J., Zhou J. 1998; Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240:147–157
    [Google Scholar]
  25. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. 1993; Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. Journal of Virology 67:1936–1944
    [Google Scholar]
  26. Rose R. C., Reichman R. C., Bonnez W. 1994a; Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. Journal of General Virology 75:2075–2079
    [Google Scholar]
  27. Rose R. C., Bonnez W., Da Rin C., McCance D. J., Reichman R. C. 1994b; Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. Journal of General Virology 75:2445–2449
    [Google Scholar]
  28. Stannard L. M., Marais D., Kow D., Dumbell K. R. 1998; Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin. Journal of General Virology 79:1637–1646
    [Google Scholar]
  29. Suzich J. A., Ghim S. J., Palmer-Hill F. J., White W. I., Tamura J. K., Bell J. A., Newsome J. A., Jenson A. B., Schlegel R. 1995; Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proceedings of the National Academy of Sciences USA 92:11553–11557
    [Google Scholar]
  30. White W. I., Wilson S. D., Bonnez W., Rose R. C., Koenig S., Suzich J. A. 1998; In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. Journal of Virology 72:959–964
    [Google Scholar]
  31. Zinkernagel R. M., Cooper S., Chambers J., Lazzarini R. A., Hengartner H., Arnheiter H. 1990; Virus-induced autoantibody response to a transgenic viral antigen. Nature 345:68–71
    [Google Scholar]
/content/journal/jgv/10.1099/0022-1317-80-9-2471
Loading
/content/journal/jgv/10.1099/0022-1317-80-9-2471
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error